(C) Wolf G Kroner 2012 - Leroy HoodMetrics for Disease, Health, and Wellness

November 2012. From the perspective of systems biology DNA sequencing is much more than a commodity service for research purposes bringing down cost of human genetic diagnostics. What is the role of microfluidics when targeting organ-specific disease biomarkers or performing wellness assays? What means “normal health state”. How to cope with noise in biological systems in a high throughput approach. In an exclusive interview with B2Bioworld Dr Leroy Hood, President of the Seattle Institute for Systems Biology shares his experience with technologies and offers insights into tasks ahead.


If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 4 pages

Full Company License enquire here

Back to section

Related Editorial Articles

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, former Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Systems Biology: In Search of Good Questions
Walter Kolch on the approach taken by Systems Biology Ireland

Systems Biology Applied
Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine, on the need of systems theory thinking in using technologies and pitfalls of some concepts.

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities. B2Bioworld asked Bruno Poddevin, Eurofins Genomics Services

Handling Suppliers of Mass Spectrometers Delicately
Michael P. Myers, Group Leader, Protein Networks at the International Centre for Genetic Engineering and Biotechnology, Trieste (IT) tells how he is avoiding to get trapped by manufacturers of mass spectrometers and their strategies to fend off competitors with proprietary data formats.

Thermo Fisher’s BRIMS-Strategy Under Testing

The Myriad Way
Peter D Meldrum, at the time CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia